AbbVie (ABBV) is planning to launch an offering of as many as seven series of senior notes, according to a regulatory filing on Tuesday.
AbbVie said it intends to use the net proceeds to repay amounts under its 364-day delayed draw term loan facility, of which $2 billion is currently outstanding, as well as for general corporate purposes, which may include the repayment or repurchase of outstanding debt.
The longest part of the offering is a bond maturing in 2066, which could potentially be priced at 1.25 percentage points over the benchmark, Bloomberg reported on Tuesday, citing a source with knowledge of the deal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.